Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

This study has been completed.
Sponsor:
Information provided by:
Cadence Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00493246
First received: June 27, 2007
Last updated: January 1, 2011
Last verified: January 2011
  Purpose

We are doing this study to find out what happens to acetaminophen in the body after it is given to children through the vein. Children's bodies may handle drugs differently than adults. Understanding how long the drug stays in the body and how the drug is changed or metabolized by the body (called pharmacokinetics) is an important step in learning what the best dose of acetaminophen for children should be. We are also interested in learning about the safety of this medication when given to children.


Condition Intervention Phase
Pain
Fever
Drug: IV Acetaminophen
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever

Resource links provided by NLM:


Further study details as provided by Cadence Pharmaceuticals:

Primary Outcome Measures:
  • Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen [ Time Frame: Time Zero (just prior to first dose) to 24 hours post first dose ] [ Designated as safety issue: No ]
    Cmax: Maximum Plasma Concentration

  • Single-dose Time to Reach Maximum Plasma Concentraton [Tmax(h)] Pharmacokinetics of IV Acetaminophen [ Time Frame: Time Zero (just prior to first dose) to 24 hours post first dose ] [ Designated as safety issue: No ]
    Tmax: Time to reach maximum plasma concentration (Cmax)

  • Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen [ Time Frame: Time Zero (just prior to first dose) to 48 hours post first dose ] [ Designated as safety issue: No ]
    AUC 0-t (µg*h/ml): Area under the plasma concentration versus time curve from time 0 (predose) to the time of the dosing interval at steady-state.

  • Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen [ Time Frame: 48hrs ] [ Designated as safety issue: No ]
    t1/2: Terminal elimination half-life


Secondary Outcome Measures:
  • Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) [ Time Frame: First dose of study medication to 30 days after the last dose of study medication ] [ Designated as safety issue: Yes ]
    A TEAE is defined as an adverse event that starts on or after the start of study medication

  • Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE) [ Time Frame: First dose to 30 days following last dose of study medication ] [ Designated as safety issue: Yes ]
    A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV acetaminophen that; Results in Death, Is life-threatening, Reguires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is an important medical event


Enrollment: 75
Study Start Date: June 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)
Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
Drug: IV Acetaminophen

This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)

Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen

Other Names:
  • APAP
  • IV APAP
Experimental: Intravenous (IV) Acetaminophen 12.5 (mg/kg)
Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
Drug: IV Acetaminophen

This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)

Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen

Other Names:
  • APAP
  • IV APAP

Detailed Description:

A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever

  Eligibility

Ages Eligible for Study:   up to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

To be eligible for entry into the Study, Subjects must meet or Subjects' Parent or Guardian must meet, agree with or confirm all of the following criteria:

  1. Provide written Informed Consent/Assent prior to participation in the Study
  2. Age strata:

    • Full-term Neonates (≤ 28 days old and minimum post conception age of 37 weeks at birth)
    • Infants [29 days to <2 years (yrs) old]

      • 29 days to <6 months
      • 6 to <12 months
      • 12 to <24 months)
    • Children (2 yrs to <12 yrs old)
    • Adolescents (12 yrs to ≤16 yrs old)
  3. Inpatient status: are currently inpatients or have an admission scheduled and will soon become an inpatient (e.g., elective surgery)
  4. Diagnosis: requires or will require analgesic treatment for acute pain or antipyretic treatment for fever
  5. IV access: have a need for IV access for the duration of the Study either due to a nothing by mouth (NPO) status or due to the Investigator's assessment that oral treatment is not optimal (for example, severe nausea or vomiting)
  6. The Subject's Parent/Guardian must have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff
  7. Be free of other physical, mental, or medical conditions which, in the opinion of the Investigator after completing the screening assessment, make Study participation inadvisable
  8. If a female of child bearing potential, have a negative pregnancy test

Exclusion Criteria (Screening)

A Subject is NOT eligible for entry if ANY of the following criteria are met:

  1. Is not able to comply with the plasma sampling requirements of the Study
  2. Has known or suspected hypersensitivity to acetaminophen or the inactive excipients of IV Acetaminophen.
  3. Has been taking any acetaminophen-containing product in the 12 hours prior or any of the following in the 48 hours prior to randomization in the Study: probenecid, disulfiram, isoniazide, St. John's wort, skullcap, chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, and valerian
  4. Has any significant medical condition that in the opinion of the Investigator contraindicates participation in the Study
  5. Has impaired liver function, with evidence of clinically significant liver disease, or other condition that may suggest the potential for an increased susceptibility to hepatic toxicity with IV APAP exposure. For this criterion, a total bilirubin greater than 1.5 times upper limit of normal (ULN) for age or an Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) or Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT) greater than 2.5 times ULN for age will be deemed as evidence of clinically significant (Common Terminology Criteria for Adverse Events [CTCAE] Grade 2) liver dysfunction or disease.
  6. Has significantly impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula) calculated to be less than 1/3rd of normal for the applicable age strata
  7. Has participated in another interventional clinical Study (investigational or marketed product) within 30 days of the planned Study randomization date
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00493246

Locations
United States, California
Lucile Packard Children's Hospital
Stanford, California, United States, 94305
United States, Michigan
CS Mott Childrens Hospital
Ann Arbor, Michigan, United States, 48109
United States, North Carolina
Duke University Health Systems
Durham, North Carolina, United States, 27710
United States, Pennsylvania
Children's Hospital Of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children's Hospital Of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Cadence Pharmaceuticals
Investigators
Study Director: Mike Royal, MD, JD, MBA Cadence Pharmaceuticals
  More Information

No publications provided

Responsible Party: Mike Royal MD JD MBA, VP Clinical Develpment Analgesics, Cadence Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00493246     History of Changes
Other Study ID Numbers: CPI-APA-102
Study First Received: June 27, 2007
Results First Received: September 25, 2009
Last Updated: January 1, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Acetaminophen
Analgesics
Analgesics, Non-Narcotic
Antipyretics
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014